Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer
Johnson E, Klimstra D, Herndon J, Catalano E, Canellos G, Graziano S, Kern J, Green M. Aberrant p53 Staining Does Not Predict Cisplatin Resistance in Locally Advanced Non-Small Cell Lung Cancer. Cancer Investigation 2002, 20: 686-692. PMID: 12197224, DOI: 10.1081/cnv-120003537.Peer-Reviewed Original ResearchConceptsCell lung cancerP53 stainingResistance to cisplatinLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerLung cancerMediastinal lymph node specimensNon-small cell lung cancerLeukemia Group B protocolsNonsmall cell lung cancerTumor resistance to cisplatinPartial resection ratePositive p53 stainingPost-operative chemotherapyResponse to chemotherapyAberrant p53 stainingGroup B protocolMutation of p53Lymph node specimensResistance in vitroPlatinum regimensMedian survivalStage IIIAResection rateStaging mediastinoscopy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply